Abstract
Traumatic brain injury (TBI) is an important public health concern plagued by high rates of mortality and significant long-term disability in many survivors. Post-traumatic seizures (PTS) are not uncommon following TBI, both in the early (within 7 days post-injury) and late (after 7 days post-injury) period. Due to the potential of PTS to exacerbate secondary injury following TBI and the possibility of developing post-traumatic epilepsy (PTE), the medical community has explored preventative treatment strategies. Prophylactic antiepileptic drug (AED) administration has been proposed as a measure to reduce the incidence of PTS and the ultimate development of PTE in TBI patients. In this topical review, we discuss the pathophysiologic mechanisms of early and late PTS and the development of PTE following TBI, the pharmacodynamic and pharmacokinetic properties of AEDs commonly used to prevent post-traumatic seizures, and summarize the available clinical evidence for employing AEDs for seizure prophylaxis after TBI.
Keywords: Antiepileptic drugs, post-traumatic seizure, prophylaxis, traumatic brain injury, post-traumatic epilepsy (PTE), antiepileptic drug (AED).
Current Pharmaceutical Design
Title:Antiepileptics for Post-Traumatic Seizure Prophylaxis after Traumatic Brain Injury
Volume: 23 Issue: 42
Author(s): Alexander G. Chartrain, Kurt Yaeger, Rui Feng, Marios S. Themistocleous, Neha S. Dangayach, Konstantinos Margetis and Zachary L. Hickman*
Affiliation:
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY,United States
Keywords: Antiepileptic drugs, post-traumatic seizure, prophylaxis, traumatic brain injury, post-traumatic epilepsy (PTE), antiepileptic drug (AED).
Abstract: Traumatic brain injury (TBI) is an important public health concern plagued by high rates of mortality and significant long-term disability in many survivors. Post-traumatic seizures (PTS) are not uncommon following TBI, both in the early (within 7 days post-injury) and late (after 7 days post-injury) period. Due to the potential of PTS to exacerbate secondary injury following TBI and the possibility of developing post-traumatic epilepsy (PTE), the medical community has explored preventative treatment strategies. Prophylactic antiepileptic drug (AED) administration has been proposed as a measure to reduce the incidence of PTS and the ultimate development of PTE in TBI patients. In this topical review, we discuss the pathophysiologic mechanisms of early and late PTS and the development of PTE following TBI, the pharmacodynamic and pharmacokinetic properties of AEDs commonly used to prevent post-traumatic seizures, and summarize the available clinical evidence for employing AEDs for seizure prophylaxis after TBI.
Export Options
About this article
Cite this article as:
Chartrain G. Alexander, Yaeger Kurt , Feng Rui, Themistocleous S. Marios, Dangayach S. Neha , Margetis Konstantinos and Hickman L. Zachary*, Antiepileptics for Post-Traumatic Seizure Prophylaxis after Traumatic Brain Injury, Current Pharmaceutical Design 2017; 23 (42) . https://dx.doi.org/10.2174/1381612823666171031100139
DOI https://dx.doi.org/10.2174/1381612823666171031100139 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Type Specificity of GABAA Receptor Mediated Signaling in the Hippocampus
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot Topic: Calcium Regulatory Proteins as Therapeutic Targets (Guest Editor: Livia C. Hool)]
Current Drug Targets <i>Rhanterium suaveolens</i>, Vitamin E and C Pretreatment Prevents Valproic Acid Induced Renal Oxidant Damage
The Natural Products Journal Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Preface [Hot Topic: New Clinical Applications for Naturally Occurring Peptide Toxins (Guest Editors: Robert Jones / Graeme Semple)]
Current Medicinal Chemistry QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry